Aclaris Therapeutics Announces Positive Results from Phase 2b Clinical Trial … – Business Wire (press release)
Aclaris Therapeutics Announces Positive Results from Phase 2b Clinical Trial …Business Wire (press release)In the trial, A-101 demonstrated clinically and statistically significant improvements in clearing multiple seborrheic keratoses (SK), one of the most common types of skin tumors. Though the lesions are benign, many patients elect to have SK treated …and more »
[monetize id=”1″] [monetize id=”2″]
Aclaris Therapeutics' Lead Drug Candidate A-101 Achieves Statistically Significant Results in Third Phase 2 Clinical …
Aclaris Therapeutics, Inc. Today announced statistically significant results from a Phase 2 clinical trial of its lead drug candidate, A-101. In the trial, A-101 demonstrated clinically and statistically significant improvements in removing seborrheic keratosis lesions on the face.
https://www.dpsw.org/keratosis-pilari
